.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,040,562

« Back to Dashboard

Claims for Patent: 9,040,562

Title:Macrocyclic inhibitors of hepatitis C virus
Abstract: Inhibitors of HCV replication of formula (I) ##STR00001## and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R.sup.1 is --OR.sup.7, --NH--SO.sub.2R.sup.8; R.sup.2 is hydrogen, and where X is C or CH, R.sup.2 may also be C.sub.1-6alkyl; R.sup.3 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.3-7cycloalkyl; R.sup.4 is aryl or Het; n is 3, 4, 5, or 6; R.sup.5 is halo, C.sub.1-6alkyl, hydroxy, C.sub.1-6alkoxy, phenyl, or Het; R.sup.6 is C.sub.1-6alkoxy, or dimethylamino; R.sup.7 is hydrogen; aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; R.sup.8 is aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
Inventor(s): Simmen; Kenneth Alan (Tervuren, BE), De Kock; Herman Augustinus (Arendonk, BE), Raboisson; Pierre Jean-Marie Bernard (Sterrebeek, BE), Nilsson; Karl Magnus (Goteborg, SE), Samuelsson; Bengt Bertil (Skarholmen, SE), Rosenquist; Asa Annica Kristina (Huddinge, SE)
Assignee: Janssen R&D Ireland (Eastgate, Country Cork, IE) Medivir AB (Huddinge, SE)
Application Number:14/285,854
Patent Claims: 1. A sodium salt of ##STR00194##

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a sodium salt of ##STR00195##

3. A combination comprising: (a) a sodium salt of ##STR00196## and (b) another anti-HCV compound.

4. The combination according to claim 3, wherein the other anti-HCV compound is an HCV polymerase inhibitor, an HCV protease inhibitor, an inhibitor of another target in the HCV life cycle, an immunomodulatory agent, an antiviral agent, or combinations thereof.

5. The combination according to claim 4, wherein the other anti-HCV compound is an HCV polymerase inhibitor.

6. The combination according to claim 4, for simultaneous, separate, or sequential use in the treatment of HCV infections.

7. The combination according to claim 5, for simultaneous, separate, or sequential use in the treatment of HCV infections.

8. The combination according to claim 3 comprising the sodium salt of ##STR00197## ribavirin, and pegylated interferon-.alpha..

9. A method of inhibiting HCV replication comprising administering to a patient in need thereof, a sodium salt of ##STR00198##

10. A method of inhibiting HCV replication comprising administering to a patient in need thereof, a sodium salt of ##STR00199## in combination with another compound.

11. The method according to claim 10, wherein the other compound is another anti-HCV compound.

12. The method according to claim 11, wherein the other anti-HCV compound is an HCV polymerase inhibitor, an HCV protease inhibitor, an inhibitor of another target in the HCV life cycle, an immunomodulatory agent, an antiviral agent, or combinations thereof.

13. The method according to claim 11, wherein the other anti-HCV compound is an HCV polymerase inhibitor.

14. The method according to claim 12, wherein the combination is administered simultaneously, separately, or sequentially in the treatment of the HCV replication inhibition.

15. The method according to claim 13, wherein the combination is administered simultaneously, separately, or sequentially in the treatment of the HCV replication inhibition.

16. The method according to claim 10, wherein the combination comprises the sodium salt of ##STR00200## ribavirin; and pegylated interferon-.alpha..
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc